TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01104779
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study: NCT00810576
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
Study: NCT00810576
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
Study: NCT00006043
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00119002
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mg/kg dexamethasone
Study: NCT03989557
Drug: Aspirin and clopidogrel/Ticagrelor
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
Study: NCT01090830
Drug: Belinostat, carboplatin, paclitaxel and bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles.
Study: NCT03989557
Drug: Aspirin and clopidogrel/Ticagrelor
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: maintenance dose of aspirin, clopidogrel and ticagrelor.
Study: NCT02350725
Drug: Furosemide injection solution for subcutaneous administration (80 mg)
Normalized name: furosemide Injectable Solution
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02208986
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin is given by s.c injection for ovulation triggering.
Study: NCT02537366
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01935466
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ever users of Pioglitazone
Study: NCT02350725
Drug: Oral Furosemide tablets (80 mg)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02802449
Drug: 25 Hydroxy- Vitamin D3 [25 (OH) D3]
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
Study: NCT02216513
Drug: desferrioxamine (DFO)
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
Study: NCT04498403
Drug: Crisaborole 2%
Normalized name: CRISABOROLE 2% OINT,TOP
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crisaborole 2% ointment
Study: NCT00599521
Drug: Adapalene lotion 0.1%
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
Study: NCT00599521
Drug: Adapalene Lotion Vehicle
Normalized name: adapalene Topical Lotion
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle will be applied topically to the face, once a day, for 12 weeks
Study: NCT02044406
Drug: BI 1181181
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose (low to high dose)
Study: NCT03760003
Drug: ABX464 25mg
DrugBank: ABX-464 (DB14828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
Study: NCT00922272
Drug: SPD489 (lisdexamfetamine dimesylate)
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, 20, 30, 40, 50, 60, or 70 mg once daily
Study: NCT00922272
Drug: Placebo matching SPD489 (lisdexamfetamine dimesylate)
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, once daily
Study: NCT02084602
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Orally administration of artesunate 4mg/Kg by three days
Study: NCT02084602
Drug: Mefloquine
Normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
Study: NCT01293539
Drug: Melphalan hydrochloride
Normalized name: melphalan hydrochloride
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (\>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle.
Study: NCT03849183
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
Study: NCT02588950
Drug: U-500R
Normalized name: U-0126
DrugBank: U-0126 (DB17060)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005634
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01167257
Drug: Liposome encapsulated botulinum toxin A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
Study: NCT01167257
Drug: Normal saline instillation
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
Study: NCT00654290
Drug: Amiodarone + Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
Study: NCT04305587
Drug: PF-07081532
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Drug once daily for up to 42 days; multiple ascending dose design.
Study: NCT04305587
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
Study: NCT01367665
Drug: vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg once daily until disease progression or unacceptable toxicity
Study: NCT00609518
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
Study: NCT00654290
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone treated 7 days pre-operation to 5 days post CABG
Study: NCT00654290
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol from 7 days pre-operation to 5 days post CABG
Study: NCT00609518
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg taken orally \[or equivalent\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
Study: NCT00609518
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg taken orally \[or equivalent\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
Study: NCT01539135
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
Study: NCT03271450
Drug: Dabigatran: extended treatment (e.g at least 90 days)
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 days
Study: NCT03271450
Drug: Dabigatran: extended treatment (e.g at least 180 days)
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 days
Study: NCT03271450
Drug: Dabigatran: extended treatment (e.g at least 270 days)
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 days
Study: NCT03271450
Drug: Apixaban: extended treatment (e.g at least 90 days)
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 90 days
Study: NCT03271450
Drug: Apixaban: extended treatment (e.g at least 180 days)
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 180 days
Study: NCT03271450
Drug: Apixaban: extended treatment (e.g at least 270 days)
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 270 days
Study: NCT03271450
Drug: Rivaroxaban: extended treatment (e.g at least 90 days)
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 90 days
Study: NCT03271450
Drug: Rivaroxaban: extended treatment (e.g at least 180 days)
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 180 days
Study: NCT03271450
Drug: Rivaroxaban: extended treatment (e.g at least 270 days)
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 270 days
Study: NCT03271450
Drug: Edoxaban: extended treatment (e.g at least 90 days)
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 90 days
Study: NCT03271450
Drug: Edoxaban: extended treatment (e.g at least 180 days)
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 180 days
Study: NCT03271450
Drug: Edoxaban: extended treatment (e.g at least 270 days)
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 270 days
Study: NCT03271450
Drug: Warfarin: extended treatment (e.g at least 90 days)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 days
Study: NCT02049450
Drug: ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
Study: NCT04331938
Drug: Regional anesthetic SPG block-bilateral
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
Study: NCT01480843
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
Study: NCT03994783
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
Study: NCT03994783
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of methylprednisolone
Study: NCT03994783
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
Study: NCT00914953
Drug: oxytocin (Pitocin)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 IU OT intranasally (IN) once-daily for 10 consecutive days
Study: NCT00601874
Drug: Pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01752543
Drug: Conivaptan
Normalized name: Conivaptan
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
Study: NCT01467414
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected s.c. (under the skin) once daily for 6 days
Study: NCT02585934
Drug: RVT-101
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral, 35 mg tablets
Study: NCT00154271
Drug: Valsartan, Valsartan HCT
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01830205
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00541216
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01996618
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
Study: NCT02674906
Drug: ACD-A
Normalized name: ACD-A Solution
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of ACD-A as anticoagulant after blood salvage during cardiac surgery
Study: NCT00566007
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
Study: NCT00566007
Drug: Oxygen therapy
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
Study: NCT00317707
Drug: N-3 Polyunsaturated Fatty Acids
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
Study: NCT06455007
Drug: Propolis
Normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propolis 3x10 drops (7 days)
Study: NCT00132028
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02140411
Drug: Ranibizumab Intravitreal injections
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
Study: NCT00002444
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02240030
Drug: CVT-301 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02240030
Drug: CVT-301 High Dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01016886
Drug: perindopril OR bisoprolol OR placebo
Normalized name: Medicated Pad or Tape
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg
Study: NCT02212613
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
Study: NCT00001398
Drug: Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
Normalized name: antihemophilic factor, human recombinant
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03839823
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
Study: NCT03839823
Drug: Letrozole OR Anastrozole
Normalized name: Anastrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician.
Study: NCT03839823
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant
Study: NCT02988024
Drug: Pristiq
Normalized name: Pristiq
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04557020
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
Study: NCT04557020
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
Study: NCT04557020
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
Study: NCT00835965
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 5 mg administered intravenously following endotracheal intubation
Study: NCT00835965
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
Study: NCT03628625
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: total dose 7.5 mg per day for 3 days
Study: NCT03628625
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprosrol 800mcg will be given to all patients for induction of abortion
Study: NCT01381666
Drug: hypertonic saline 3% sodium chloride solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhalation via nebulizer given for 2 doses for 60 minutes each
Study: NCT01056042
Drug: intramuscular depot medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg, Intramuscular, every 3 months
Study: NCT03574948
Drug: 5-HTP
Normalized name: 5-HTP
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks active substance 5-HTP (2 x 100mg per day)
Study: NCT04047186
Drug: Nivolumab Injection
Normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
Study: NCT03589040
Drug: Etonogestrel 68Mg Implant
Normalized name: ETONOGESTREL 68MG IMPLANT
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
Study: NCT03589040
Drug: rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral rilpvirine 25mg
Study: NCT03589040
Drug: darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral darunavir+ritonavir 600/100mg
Study: NCT04838548
Drug: MRG003
DrugBank: MRG-003 (DB17407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT02686645
Drug: vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
Study: NCT02686645
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.